 |
One Dose at a Time: Mobilizing to Eliminate Cervical Cancer In Nigeria
This past October, Nigeria introduced single-dose human papillomavirus (HPV) vaccination into its routine immunization schedule for adolescent girls. Dr. Chizoba Wonodi, IVAC's Nigeria Country Director, worked with UNICEF, Gavi, the Vaccine Alliance, WHO, and other partners to launch this historic campaign with the hope of eliminating cervical cancer deaths in the country. |
|
 |
Eliminating Cervical Cancer Through HPV Vaccination
In recognition of Cervical Cancer Awareness Month, we are highlighting various IVAC resources related to HPV vaccination, which is a major pillar in the World Health Organization’s strategy to eliminate cervical cancer as a public health problem. Cervical cancer is the fourth leading type of cancer among women, impacting more than 600,000 women around the world each year. To learn more about how HPV vaccination can protect girls and women against this disease, explore the resources below.
The Power of A Single Dose: Evidence for a Single-Dose HPV Vaccine Schedule
This new Evidence Brief, published by IVAC’s Value of Immunization Compendium of Evidence (VoICE), synthesizes and translates the latest research on single-dose HPV vaccination into messaging that can be used by advocates, policymakers, and researchers.
HPV Vaccine Module on VIEW-hub
VIEW-hub, IVAC’s open access data visualization tool, includes a module tracking HPV vaccine introduction and use across 194 countries. Users can explore and download the latest data on dosing schedules, distribution sites, target populations, and more.
Understanding Priorities and Needs for HPV Vaccine Advocacy: Findings from a Global Survey
This report summarizes findings from a survey of global immunization stakeholders examining which topics, audiences, and approaches may be most important to inform future HPV vaccine advocacy efforts.
HPV Vaccine Acceleration Program Partners Initiative (HAPPI)
IVAC is proud to collaborate with JSI, Clinton Health Access Initiative, Jhpiego, and PATH on the HPV Vaccine Acceleration Program Partners Initiative (HAPPI). This consortium aims to increase HPV vaccine uptake in low- and middle-income countries through technical assistance; targeted learning, measurement, and evaluation; and translation of lessons learned into policy, guidelines, and practices.
|
|
WHO Prequalifies nOPV2 Polio Vaccine
Last month, the WHO granted prequalification approval for the novel oral polio vaccine type 2 (nOPV2), a next-generation polio vaccine that has already been used to safely and effectively protect millions of children against this devastating disease. This decision will allow more countries to access this life-saving vaccine. “nOPV is a critical tool in stopping outbreaks of circulating vaccine-derived polio and ultimately achieving polio eradication,” says Dr. Svea Closser, an IVAC faculty member and Associate Professor at the Johns Hopkins Bloomberg School of Public Health. |
|
|
Equity in Vaccine Coverage in Uganda from 2000 to 2016: Revealing the Multifaceted Nature of Inequity [BMC Public Health]
Authors include Gatien de Broucker, Joshua Mak, and Bryan Patenaude
This publication from IVAC's VERSE team analyses vaccine coverage and equity among children under 5 in Uganda. Researchers found that the past two decades have seen significant improvements in vaccine coverage and equity among this population, though further improvements could be achieved by targeting the districts with the highest inequity, increasing maternal education, and prioritizing vaccine delivery to the urban-poor population. |
|
|
|
|
|
|
